Skip to main content Homepage



COVID-19 Information & Resources

For pharmacy specific information, see: COVID-19 UPDATED Oregon Board of Pharmacy Information 3/3/2021

Important Announcement 4/13/2021

Please pause all use of the Johnson & Johnson (J&J) COVID-19 vaccine immediately, in accordance with this joint announcement from CDC and FDA this morning (4/13/2021).

This recommendation is made in the wake of reports of six cases of cerebral venous sinus thrombosis in women 18–48 years of age, with approximately 6.8 million doses of J&J vaccine administered to date. Symptoms in these patients began 6–13 days following vaccination.

CDC is convening its Advisory Committee on Immunization Practices (ACIP) April 14, 2021 to review the relevant data. This pause in vaccination is recommended until ACIP and FDA review are completed. Today, CDC and FDA will provide additional information and answer questions at a media briefing.

These cases were flagged in the Vaccine Adverse Events Reporting System (VAERS), a component of national post-licensure vaccine safety monitoring. People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. 

Health care providers are asked to report adverse events to the Vaccine Adverse Event Reporting System at

The CDC and FDA’s statement reminds health care providers that administration of heparin, normally used to treat blood clots, may be dangerous in the setting of cerebral venous sinus thrombosis, and alternative treatments need to be given. 

As of April 12, there have been 81,255 Johnson & Johnson vaccine doses administered in Oregon and 212,100 doses of the Johnson & Johnson vaccine delivered to vaccine sites statewide.  This vaccine has been delivered to a combination of sites in Oregon, including pharmacies, outpatient clinics, federally qualified health centers, local public health authorities and health systems.

Joint CDC and FDA announcement:

This notification is being shared widely amongst the Oregon Healthcare Community, LPHAs, Tribes, and Hospitals.

Oregon 24/7 disease reporting: 971-673-1111 

Additional Public Health Emergency Information

In order to help contain the spread of the coronavirus (COVID-19), the Oregon Board of Pharmacy has closed its offices to the general public and board staff will be following the physical distancing measures outlined in Governor Brown's Executive Order No. 21-05. 

If you need to contact the board, send your inquiries to one of the email addresses listed below:

Please be advised that it may take longer than usual to receive a response, however staff will reply as soon as possible. 

For the latest information on Novel Coronavirus (COVID-19) in Oregon, visit the Oregon Health Authority.

Your browser is out-of-date! It has known security flaws and may not display all features of this and other websites. Learn how